Bse healthcare

The Indian market also saw slower growth partly because of the problems relating to the ban on certain fixed-dose combinations, the inclusion of more drugs in the price control list and cuts in existing drugs under price control due to negative wholesale price inflation (the benchmark used to determine price changes). Photo: Hemant Mishra/Mint

Pharma: regulatory logjam continues

1 min read . 09 Oct 2016